Market cap
$1 Mln
Recently Viewed
Clear All$0.02
$-0.01
(-23.45%)
As on 03-Oct-2024 16:00EDT
Market cap
$1 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-6 Mln
ROE
-16.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.3
Debt to Equity
0
Book Value
$--
EPS
$-4.5
Face value
--
Shares outstanding
30,737,800
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Comera Life Sciences Holdings Inc (CMRA)
| -59.6 | -- | -- | -92.6 | -87.0 | -- | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Comera Life Sciences Holdings Inc (CMRA)
| -95.5 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Comera Life Sciences Holdings Inc (CMRA)
|
0.0 | 0.7 | 1.0 | -84.3 | -917.2 | -- | -- | 0.0 |
| 1.8 | 60.8 | 1.5 | -56.5 | -4,286.6 | -68.3 | -- | 0.8 |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion... of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts. Read more
CEO, CFO & Principal Accounting Officer
Mr. Michael G. Campbell CPA
CEO, CFO & Principal Accounting Officer
Mr. Michael G. Campbell CPA
Headquarters
Woburn, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Comera Life Sciences Holdings Inc (CMRA) is $0.02 (NASDAQ) as of 03-Oct-2024 16:00 EDT. Comera Life Sciences Holdings Inc (CMRA) has given a return of -86.98% in the last 3 years.
Since, TTM earnings of Comera Life Sciences Holdings Inc (CMRA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.53
|
-2.06
|
|
2021
|
-36.54
|
-13.17
|
|
2020
|
--
|
--
|
|
2022
|
-0.53
|
-2.06
|
|
2021
|
-36.54
|
-13.17
|
The 52-week high and low of Comera Life Sciences Holdings Inc (CMRA) are Rs -- and Rs -- as of 25-Apr-2026.
Comera Life Sciences Holdings Inc (CMRA) has a market capitalisation of $ 1 Mln as on 03-Oct-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Comera Life Sciences Holdings Inc (CMRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.